1. Home
  2. AVLN vs UAN Comparison

AVLN vs UAN Comparison

Compare AVLN & UAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

N/A

Current Price

$29.23

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Logo CVR Partners LP

UAN

CVR Partners LP

HOLD

Current Price

$114.29

Market Cap

1.1B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVLN
UAN
Founded
N/A
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Agricultural Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
2026
2008

Fundamental Metrics

Financial Performance
Metric
AVLN
UAN
Price
$29.23
$114.29
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
545.5K
30.1K
Earning Date
N/A
04-29-2026
Dividend Yield
N/A
7.91%
EPS Growth
N/A
61.98
EPS
N/A
4.72
Revenue
N/A
$606,038,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$24.99
Revenue Growth
N/A
15.36
52 Week Low
$27.33
$86.23
52 Week High
$33.32
$139.50

Technical Indicators

Market Signals
Indicator
AVLN
UAN
Relative Strength Index (RSI) 35.88 46.85
Support Level $27.37 $107.10
Resistance Level $33.32 $119.90
Average True Range (ATR) 2.54 3.19
MACD -0.26 1.08
Stochastic Oscillator 31.72 58.23

Price Performance

Historical Comparison
AVLN
UAN

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

About UAN CVR Partners LP

CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.

Share on Social Networks: